Skip to main content
. 2021 Dec 7;216:125–128. doi: 10.1016/j.thromres.2021.12.003

Table 2.

Primary, secondary, exploratory, and safety outcomes.

Outcomes Standard-dose anticoagulation (n = 5) Therapeutic-dose anticoagulation (n = 5) Tissue plasminogen activator (n = 5)
Primary outcome
Median of percent change of P./F ratio within 48 h of enrollmenta (Q1, Q3)b −15.8 (−28.0–24.1) −7.6 (−14.5–68.9) 7.1 (−19.5–8.4)



Other outcomes
In-hospital mortality (%) 4 (80) 2 (40) 5 (100)
Median difference of the SOFA score within 48 h of enrollmentc (Q1, Q3) 1 (0–1) 0 (−1–0) 1 (0–2)
ICU discharge (%) 1 (20) 3 (60) 0 (0)
ICU stays (d) 11 (8–12) 8 (4–19) 7 (6–10)
Hospital stays (d) 11 (8–16) 16 (8–20) 7 (6–10)
Cerebrovascular accident (%) 0 0 0
Major bleedingd (%) 0 0 0
Severe thrombocytopeniae (%) 0 (0) 1 (20.0) 0 (0)
a

(Q1, Q3), interquartile range 25% - 75%.

b

P/F ratio, Partial pressure of arterial oxygen (PaO2) to the fraction of inspired oxygen (FiO2) ratio. This index is a clinical indicator of hypoxemia and acute respiratory distress syndrome severity (ARDS severity: mild 200–300, moderate 100–200, and severe <100).

c

The sequential organ failure assessment score (SOFA) is used to assess organ function status in patients admitted to the intensive care unit (ICU) according to 6 components: the respiratory, cardiovascular, hepatic, coagulation, renal, and neurological systems.

d

Major bleeding according to the International Society of Thrombosis and Haemostasis classification in nonsurgical patients.

e

Severe thrombocytopenia, defined as a platelet count <20,000 (cell/μL).